Vibrato Medical, Inc. Company Profile

Background

Vibrato Medical, Inc., headquartered in Newport Beach, California, is a pioneering medical device company dedicated to developing non-invasive therapeutic solutions for peripheral arterial disease (PAD) and chronic limb-threatening ischemia (CLTI). The company's mission is to become the preferred therapeutic system for patients with reduced tissue perfusion, offering innovative treatments that enhance patient outcomes and quality of life.

Key Strategic Focus

Vibrato Medical's strategic focus centers on the development and commercialization of its wearable therapeutic ultrasound device, designed to promote vasodilation, collateral vessel growth, and angiogenesis. This non-invasive technology aims to restore perfusion in patients suffering from PAD and CLTI, providing a convenient, home-based treatment alternative to traditional surgical interventions. The company targets the growing market of patients with reduced tissue perfusion, addressing significant unmet clinical needs.

Financials and Funding

In September 2021, Vibrato Medical secured a $4 million Series A funding round led by the Horowitz Group, a multi-asset class family investment office based in Newport Beach, California. Additionally, the company received a $1.5 million grant from the National Institutes of Health (NIH). These funds are allocated to support clinical trials, design and build the second-generation device, and advance the company's intellectual property portfolio.

Pipeline Development

Vibrato Medical is actively engaged in clinical trials to evaluate the safety and efficacy of its therapeutic ultrasound device. Notably:

Prelude Study: An early feasibility study involving 12 patients with Rutherford class 3, 4, or 5 PAD demonstrated statistically significant improvements in perfusion and tissue oxygenation. Patients received 30-40 treatment sessions over two months, resulting in a 180% increase in toe perfusion and a 17% increase in tissue oxygenation.

Waltz Study: A prospective, non-significant risk feasibility study aims to assess the acute vasodilatory and perfusion effects of the VibratoSleeve Therapeutic Ultrasound Device in subjects aged 65 and older with early-stage PAD. The study plans to enroll 12 participants, each receiving multiple treatment sessions.

Technological Platform and Innovation

Vibrato Medical's proprietary technology is a novel, non-invasive, wearable therapeutic ultrasound device designed to treat PAD and CLTI. Unlike endovascular and surgical revascularization, this device can be applied without skin incisions, allowing for home-based treatment. The technology leverages therapeutic ultrasound to promote vasodilation, collateral vessel growth, and angiogenesis, thereby restoring perfusion.

Leadership Team

Juliana Elstad: Chief Executive Officer. Elstad brings extensive experience in developing and commercializing medical devices, guiding Vibrato Medical's strategic direction and operations.

Babak Nazer, MD: Co-founder. A cardiologist and physician-scientist, Dr. Nazer's expertise in therapeutic ultrasound research underpins the company's technological innovations.

Bobak Azamian, MD, PhD: Co-founder. An entrepreneur with a background in medical technology, Dr. Azamian contributes to the company's vision and product development strategies.

Competitor Profile

Market Insights and Dynamics

Peripheral arterial disease affects over 18 million individuals in the United States, with approximately 2 million progressing to chronic limb-threatening ischemia. The market for PAD and CLTI treatments is substantial, driven by the aging population and the increasing prevalence of diabetes and cardiovascular diseases.

Competitor Analysis

Key competitors in the PAD and CLTI treatment space include:

Endovascular Device Manufacturers: Companies such as Medtronic and Boston Scientific offer catheter-based therapies, including angioplasty, stenting, and drug-coated balloons. These treatments, while effective for some patients, can be invasive and are associated with complications and high rates of long-term restenosis.

Surgical Revascularization Providers: Traditional surgical interventions, such as bypass grafting, are performed by vascular surgeons in hospital settings. These procedures are invasive, require significant recovery time, and may not be suitable for all patients.

Vibrato Medical differentiates itself by offering a non-invasive, wearable solution that can be administered at home, potentially reducing the risks and costs associated with invasive procedures.

Strategic Collaborations and Partnerships

Vibrato Medical has established significant collaborations to advance its technology:

Horowitz Group: Led the $4 million Series A funding round, providing financial support and strategic guidance.

National Institutes of Health (NIH): Awarded a $1.5 million grant to support clinical trials and device development.

Vascular & Interventional Specialists of Orange County: Partnered for clinical trials, with Dr. Mahmood Razavi serving as the principal investigator.

Operational Insights

Vibrato Medical's non-invasive, wearable therapeutic ultrasound device offers a distinct competitive advantage by providing a home-based treatment option for PAD and CLTI patients. This approach addresses the limitations of existing invasive procedures, potentially reducing healthcare costs and improving patient compliance and outcomes.